CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients
AlloSeq cfDNA Consistent with Performance of Proven AlloSure Testing CareDx Brings Innovative Non-Invasive Transplant Monitoring to Patients Internationally with AlloSeq cfDNA CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine




